SCF ENCYCLOPEDIA ENTRY

PERIPARTUM CARDIOMYOPATHY (PPCM)

SCF-RDOS Maternal Cardiac Failure, Peripartum Hemodynamic Dysregulation & Cardiomyocyte Injury Registry

Disease Classification

Maternal Cardiovascular Disease / Pregnancy-Associated Cardiomyopathy / Heart Failure Syndrome / Peripartum Organ Dysfunction Disorder / Obstetric Critical Care Condition

Master Registry Code

SCF-PPCM-0001

I. DEFINITION

Peripartum Cardiomyopathy (PPCM) is a rare but potentially life-threatening form of heart failure characterized by left ventricular systolic dysfunction that develops during the last month of pregnancy or within the months following delivery, in the absence of another identifiable cause of cardiomyopathy.

The condition is defined by:

• Reduced left ventricular ejection fraction (LVEF)
• Ventricular dilation (in some cases)
• New-onset heart failure symptoms
• Peripartum timing

PPCM may range from mild cardiac dysfunction to:

• Severe heart failure
• Cardiogenic shock
• Arrhythmias
• Sudden cardiac death

Within the Synergistic Compatibility Framework (SCF), PPCM is modeled as a:

• Maternal cardiovascular adaptation failure syndrome
• Peripartum hemodynamic synchronization disorder
• Cardiomyocyte stress-injury architecture
• Multisystem perfusion instability cascade

II. CORE SCF ETIOPATHOGENIC PRINCIPLE

Central SCF Thesis

Peripartum cardiomyopathy develops when physiologic cardiovascular adaptations of pregnancy exceed myocardial adaptive capacity, resulting in cardiomyocyte injury, ventricular dysfunction, impaired systemic perfusion, neurohormonal activation, and progressive heart failure.

This propagates through:

1. Pregnancy-induced cardiovascular stress
2. Myocardial susceptibility
3. Cardiomyocyte injury
4. Ventricular dysfunction
5. Neurohormonal activation
6. Heart failure progression
7. Maternal systemic compromise

III. MAJOR PPCM REGISTRY

A. CLASSIC PERIPARTUM CARDIOMYOPATHY

Most Common Form

Develops:

• During late pregnancy
• Within 5 months postpartum

Characterized by:

• Reduced LVEF
• Symptoms of heart failure

B. EARLY-ONSET PPCM

Develops:

• Before the final month of pregnancy

Often associated with:

• High-risk maternal conditions

C. SEVERE PPCM

Associated with:

• Markedly reduced LVEF
• Cardiogenic shock
• Mechanical circulatory support requirements

D. RECURRENT PPCM

Occurs in:

• Subsequent pregnancies

Risk increases if ventricular function remains impaired.

E. RECOVERED PPCM

Characterized by:

• Partial or complete normalization of cardiac function

May still carry future pregnancy risk.

IV. ETIOLOGIC DOMAINS

A. HEMODYNAMIC OVERLOAD

Pregnancy increases:

• Blood volume
• Cardiac output
• Ventricular workload

Excess stress may contribute to myocardial dysfunction.

B. ANGIOGENIC IMBALANCE

Evidence suggests involvement of:

• Antiangiogenic factors
• Endothelial dysfunction
• Placental signaling abnormalities

C. OXIDATIVE STRESS

Associated with:

• Reactive oxygen species accumulation
• Cardiomyocyte injury
• Mitochondrial dysfunction

D. INFLAMMATORY ACTIVATION

Includes:

• Cytokine signaling
• Immune dysregulation
• Myocardial inflammation

E. GENETIC SUSCEPTIBILITY

Associated with:

• Familial cardiomyopathy genes
• Sarcomeric protein variants
• Cardiac structural genes

F. OBSTETRIC RISK FACTORS

Associated with:

• Multiple gestation
• Advanced maternal age
• Hypertensive disorders of pregnancy

Associated with:

• Preeclampsia
• Eclampsia

V. SCF MULTI-OMIC PATHOGENESIS

A. HEMODYNAMIC STRESS LAYER

Results in:

• Increased ventricular wall stress
• Increased myocardial oxygen demand

B. ENDOTHELIAL DYSFUNCTION LAYER

Produces:

• Vascular instability
• Reduced tissue perfusion
• Angiogenic imbalance

C. CARDIOMYOCYTE INJURY LAYER

Includes:

• Oxidative injury
• Mitochondrial dysfunction
• Contractile impairment

D. NEUROHORMONAL ACTIVATION LAYER

Involves:

• Sympathetic activation
• Renin–angiotensin–aldosterone activation
• Fluid retention

E. VENTRICULAR REMODELING LAYER

Results in:

• Chamber dilation
• Reduced contractility
• Progressive dysfunction

F. HEART FAILURE LAYER

Produces:

• Reduced cardiac output
• Pulmonary congestion
• Organ hypoperfusion

VI. SCF FAULT-TIER ARCHITECTURE

SCF fault progression models PPCM as a breakdown of maternal cardiovascular adaptation mechanisms under pregnancy-associated physiologic stress.

VII. MAJOR CLINICAL MANIFESTATIONS

A. CARDIOPULMONARY FINDINGS

Includes

• Dyspnea
• Orthopnea
• Paroxysmal nocturnal dyspnea
• Exercise intolerance

B. VOLUME OVERLOAD FINDINGS

Includes

• Peripheral edema
• Pulmonary edema
• Rapid weight gain

C. CARDIAC FINDINGS

Includes

• Tachycardia
• Palpitations
• Reduced exercise tolerance
• Chest discomfort

D. SEVERE FINDINGS

Includes

• Cardiogenic shock
• Syncope
• Severe hypoperfusion

VIII. MAJOR COMPLICATIONS

Cardiac

Includes

• Chronic heart failure
• Persistent ventricular dysfunction
• Dilated cardiomyopathy

Arrhythmic

Includes

• Ventricular tachycardia
• Sudden cardiac death

Thromboembolic

Includes

• Ventricular thrombus
• Stroke
• Pulmonary embolism

Associated with:

• Pulmonary Embolism

Obstetric

Includes

• Maternal mortality
• Future pregnancy risk
• Recurrent cardiomyopathy

IX. SCF RHENOVA INTERPRETATION

Within the SCF–RHENOVA framework, PPCM represents:

• Cardiovascular bioenergetic variance
• Maternal perfusion instability
• Hemodynamic adaptation failure

Key RHENOVA Signatures

• Myocardial energy deficit
• Oxidative stress overload
• Endothelial dysfunction
• Neurohormonal amplification
• Ventricular inefficiency

X. SCF DBI INTERPRETATION

Under the SCF Decentralized Biological Intelligence (DBI) framework, the maternal cardiovascular system functions as a dynamic resource-distribution network.

PPCM disrupts:

• Circulatory intelligence pathways
• Perfusion allocation systems
• Neurohormonal coordination networks
• Cardiovascular adaptation algorithms
• Maternal–placental resource management systems

DBI Signature

Pregnancy Stress Load → Cardiomyocyte Vulnerability → Network Dysfunction → Perfusion Failure

XI. SCF PATHOGENESIS LOGIC MODEL

Reconnaissance Phase

Pregnancy imposes escalating cardiovascular demands.

Enumeration Phase

Cardiac adaptive reserve becomes insufficient.

Exploitation Phase

Cardiomyocyte injury and endothelial dysfunction emerge.

Persistence Phase

Neurohormonal activation perpetuates dysfunction.

System Failure Phase

Clinical heart failure develops.

XII. DIAGNOSTIC ARCHITECTURE

Clinical Assessment

Evaluate:

• Dyspnea
• Edema
• Fatigue
• Orthopnea

Particularly in:

• Late pregnancy
• Early postpartum period

Cardiac Imaging

Echocardiography

Primary diagnostic tool.

Evaluates:

• LVEF
• Chamber size
• Ventricular function

Laboratory Evaluation

May include:

• BNP or NT-proBNP
• Troponin
• Renal function
• Liver function

Additional Assessment

May include:

• ECG
• Cardiac MRI
• Thromboembolic evaluation

XIII. SCF PCR MODEL (PREVENTATIVE–CURATIVE–RESTORATIVE)

A. PREVENTATIVE

Risk Identification

Evaluate:

• Prior PPCM
• Family history of cardiomyopathy
• Hypertensive pregnancy disorders

Maternal Cardiovascular Optimization

Includes:

• Blood pressure control
• Weight management
• Prenatal monitoring

B. CURATIVE

Heart Failure Therapy

Depending on pregnancy status and postpartum status, may include:

• Beta Blockers
• Furosemide
• Angiotensin-Converting Enzyme Inhibitors

Anticoagulation

May be indicated in:

• Severe ventricular dysfunction
• Intracardiac thrombus risk

Advanced Therapy

May require:

• Mechanical circulatory support
• Ventricular assist devices
• Heart transplantation

C. RESTORATIVE

Recovery Monitoring

Includes:

• Serial echocardiography
• Functional assessment
• Long-term cardiovascular surveillance

Future Pregnancy Counseling

Critical for:

• Risk stratification
• Recurrence prevention
• Maternal safety planning

XIV. ORIGIN-OF-DISEASE & CYTOGENESIS PROGRESSION TIMELINE

Cytogenesis Loci

Primary loci:

• Left ventricle
• Cardiomyocytes
• Coronary microvasculature
• Endothelium

Secondary loci:

• Kidneys
• Lungs
• Neurohormonal regulatory systems
• Placental vascular signaling pathways

XV. API DISCOVERY & THERAPEUTIC PRIORITIES

High-Priority Therapeutic Domains

Cardiomyocyte Protection

Targets:

• Oxidative stress reduction
• Mitochondrial preservation
• Contractility maintenance

Angiogenic Restoration

Targets:

• Endothelial repair
• Microvascular stabilization
• Placental signaling balance

Heart Failure Modulation

Targets:

• Neurohormonal regulation
• Ventricular remodeling prevention
• Perfusion optimization

DBI-Based Discovery

Targets:

• Cardiovascular adaptation biomarkers
• Maternal hemodynamic resilience signatures
• Predictive heart-failure intelligence models

XVI. SCF SUMMARY

Peripartum Cardiomyopathy = Maternal Cardiovascular Adaptation and Perfusion Synchronization Failure Syndrome

Within SCF:

• Peripartum cardiomyopathy is a pregnancy-associated heart failure syndrome characterized by left ventricular systolic dysfunction arising during late pregnancy or the postpartum period.
• The disorder results from the interaction of hemodynamic overload, endothelial dysfunction, oxidative stress, inflammatory signaling, and genetic susceptibility.
• Clinical manifestations range from mild dyspnea to severe cardiogenic shock and death.
• Early diagnosis through echocardiography and prompt heart-failure management substantially improve outcomes.
• Future SCF therapeutic priorities focus on cardiomyocyte preservation, angiogenic restoration, precision cardiovascular monitoring, and enhancement of maternal adaptive resilience networks.